04 September 2010
Keywords: Pfizer, China, Japan, Generics,
Article | 24 November 2009
The world’s largest drugmaker, USA-based Pfizer, is eyeing the Japanese generics market and, in an investment review of the company, Goldman Sachs said sales in emerging growth markets would become a significant factor in the company's revenues, a fact that it considers underappreciated by stock market investors. China is the major emerging market for Pfizer.
Reported by numerous news sources, Goldman expects emerging growth markets to produce $3.5 billion of revenue for Pfizer in 2012, of which $3 billion of will come from China. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.